We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$2.08B
Cap. Flow %
-33.31%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.55%
2 Consumer Discretionary 7.13%
3 Consumer Staples 5.35%
4 Technology 5.24%
5 Communication Services 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEXRW
251
Nexera Technologies Ltd Warrant
NEXRW
$48.9K
$2.44K ﹤0.01%
68,682
– –
DFSCW
252
DEFSEC Technologies Warrant
DFSCW
$1.81K ﹤0.01%
120,000
– –
KTTAW icon
253
Pasithea Therapeutics Warrants
KTTAW
$5.69K
$1.75K ﹤0.01%
50,000
– –
BNCWW
254
CEA Industries Inc Warrant
BNCWW
$1.46K ﹤0.01%
58,333
– –
ACONW icon
255
Aclarion Warrant
ACONW
$49.4K
$1.2K ﹤0.01%
34,375
– –
TNONW icon
256
Tenon Medical Inc Warrant
TNONW
$1.49K
$679 ﹤0.01%
22,250
-155,750
-88% -$7.17K
IVDAW icon
257
Iveda Solutions Warrant
IVDAW
$47.8K
$366 ﹤0.01%
18,125
-126,875
-88% -$7.82K
NLSPW
258
DELISTED
NLS Pharmaceutics Warrant
NLSPW
$143 ﹤0.01%
12,500
-487,500
-98% -$14.3K
APVO icon
259
Aptevo Therapeutics
APVO
$5.21M
– –
-56
Closed -$229K
AREBW
260
DELISTED
American Rebel Holdings Warrants
AREBW
– –
-193
Closed -$276
ARMK icon
261
Aramark
ARMK
$14.7B
– –
-7,254
Closed -$247K
ASO icon
262
Academy Sports + Outdoors
ASO
$2.98B
– –
-95,627
Closed -$5.09M
BLTE
263
Belite Bio
BLTE
$6.54B
– –
-148,000
Closed -$6.76M
BN icon
264
Brookfield
BN
$108B
– –
-8,505
Closed -$236K
BMY icon
265
Bristol-Myers Squibb
BMY
$132B
– –
-490,868
Closed -$20.4M
BNGO icon
266
Bionano Genomics
BNGO
$13.3M
– –
-27,967
Closed -$1.14M
BRK.B icon
267
Berkshire Hathaway Class B
BRK.B
$1.13T
– –
-747
Closed -$304K
BTAI icon
268
BioXcel Therapeutics
BTAI
$27.8M
– –
-186,688
Closed -$3.82M
CBUS icon
269
Cibus
CBUS
$138M
– –
-516,000
Closed -$5.08M
CHH icon
270
Choice Hotels
CHH
$4.8B
– –
-60,000
Closed -$7.14M
CING icon
271
Cingulate
CING
$71.9M
– –
-40,833
Closed -$157K
CINGW icon
272
Cingulate Inc Warrants
CINGW
$33.2K
– –
-20,500
Closed -$221
CLSD
273
DELISTED
Clearside Biomedical
CLSD
– –
-142,400
Closed -$2.78M
CPRI icon
274
Capri Holdings
CPRI
$1.74B
– –
-9,629
Closed -$319K
CRL icon
275
Charles River Laboratories
CRL
$12.8B
– –
-119,071
Closed -$24.6M
9 10
11
12 13

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital withdrew a net $2.08B in Q3 2024, closing 73 positions and reducing 65 holdings. Its most notable exit was Exact Sciences, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Paramount Global Class B worth $21.2M.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.